News Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Continue Reading Previous FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%Next Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021 Related Stories News ROK-Biotech, Korea’s leading cosmetic brand, Launches the new product ‘Dr. M-KIN Anti V Hand Cream’ News Magellan Health Reports 2020 Financial Results News Clearwater Paper Announces Virtual Participation at the J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference News Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Renewable Energy Group Inc. (REGI) on Behalf of Investors News KBRA Assigns Preliminary Ratings to Pagaya AI Debt Selection Trust 2021-1 News USA Compression Partners, LP to Participate in Investor Conferences
